BackCytokinetics Overview
Cytokinetics Inc

Cytokinetics Target Price

See Cytokinetics's analyst price targets ($110) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$71.93

Average Target Price

$114.6959.4% upside

13 analysts in the last 4 months

High: $140 | Low: $103

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-13Barclays$11052.9% upsideOpen
2026-08-10Truist FinancialSrikripa Devarakonda$11255.7% upsideOpen
2026-08-07NeedhamSerge Belanger$11255.7% upsideOpen
2026-08-07RBC CapitalLeonid Timashev$11255.7% upsideOpen
2026-07-07RBC CapitalLeonid Timashev$11762.7% upsideOpen
2026-06-29UBSAshwani Verma$11559.9% upsideOpen
2026-06-24Mizuho Securities$11864% upsideOpen
2026-06-17RBC CapitalLeonid Timashev$11965.4% upsideOpen
2026-05-11H.C. Wainwright$14094.6% upsideOpen
2026-05-06Morgan Stanley$10343.2% upsideOpen
2026-05-06UBS$11965.4% upsideOpen
2026-05-06Stifel Nicolaus$10850.1% upsideOpen
2026-05-05Truist FinancialSrikripa Devarakonda$10647.4% upsideOpen
2026-04-10Wells Fargo$9532.1% upsideOpen
2026-03-10Robert W. BairdRoanna Ruiz$8416.8% upsideOpen
2026-03-06UBSAshwani Verma$694.1% downsideOpen
2026-02-20RBC Capital$10140.4% upsideOpen
2026-02-03Truist FinancialSrikripa Devarakonda$9227.9% upsideOpen
2026-01-09JefferiesAkash Tewari$9025.1% upsideOpen
2026-01-08Morgan StanleyMaxwell Skor$9025.1% upsideOpen
2025-12-22Truist FinancialSrikripa Devarakonda$8416.8% upsideOpen
2025-12-22Morgan Stanley$711.3% downsideOpen
2025-12-22Leerink PartnersRoanna Ruiz$8315.4% upsideOpen
2025-12-22RBC Capital$9532.1% upsideOpen
2025-12-22NeedhamSerge Belanger$8416.8% upsideOpen
2025-12-22Goldman Sachs$9937.6% upsideOpen
2025-12-22H.C. WainwrightJoseph Pantginis$13689.1% upsideOpen
2025-12-22Barclays$8721% upsideOpen
2025-12-18Goldman Sachs$9532.1% upsideOpen
2025-12-01UBSAshwani Verma$6115.2% downsideOpen
2025-10-06BarclaysGena Wang$8214% upsideOpen
2025-09-03Evercore ISICory Kasimov$8011.2% upsideOpen
2025-09-03BarclaysGena Wang$711.3% downsideOpen
2025-09-02Stifel NicolausJames Condulis$9633.5% upsideOpen
2025-04-24BarclaysGena Wang$5523.5% downsideOpen
2025-03-07Morgan Stanley$676.9% downsideOpen
2024-10-17H.C. WainwrightJoseph Pantginis$12066.8% upsideOpen
2024-09-03Goldman SachsPaul Choi$6016.6% downsideOpen
2024-06-10Piper SandlerYasmeen Rahimi$10748.8% upsideOpen
2024-06-04B.Riley FinancialMayank Mamtani$9227.9% upsideOpen
2024-05-28JMP SecuritiesJason Butler$788.4% upsideOpen
2024-05-23H.C. WainwrightJoseph Pantginis$9025.1% upsideOpen
2024-05-23NeedhamSerge Belanger$720.1% upsideOpen
2024-05-23JefferiesAkash Tewari$8518.2% upsideOpen
2024-05-23BarclaysCarter Gould$9532.1% upsideOpen
2024-05-09OppenheimerJustin Kim$10647.4% upsideOpen
2024-05-09JMP SecuritiesJason Butler$10647.4% upsideOpen
2024-04-05Mizuho SecuritiesSalim Syed$9937.6% upsideOpen
2022-12-23Needham$5819.4% downsideOpen
2022-12-20Truist Financial$6016.6% downsideOpen

Cytokinetics (CYTK) FAQ

Cytokinetics's target price stands at $110. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $110 for CYTK implies 59.4% upside versus today's price ($71.93). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Cytokinetics's target price evolved across reporting periods, while the comparison chart places CYTK next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Cytokinetics's reading of $110 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.